Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma

British Journal of Haematology

Volumn 123, Issue 2, 2003, Pages 305-308

  Thompson, Michael A ^a   Witzig, Thomas E ^a   Kumar, Shaji ^a   Timm, Michael M ^a   Haug, Jessica ^a   Fonseca, Rafael ^a   Greipp, Philip R ^a   Lust, John A ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Cytokines; Multiple myeloma; Prognosis; Therapy

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; DEXAMETHASONE; INTERLEUKIN 6; INTERLEUKIN 8; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE MARROW; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CHEMICAL PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY; DEVICE; DISEASE COURSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MICROVASCULATURE; MULTIPLE MYELOMA; MYELOMA CELL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BONE MARROW; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL ANALYSIS; THALIDOMIDE; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0142246501     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04605.x     Document Type: Article

References (10)

1. Carter, A., Merchav, S., Silvian-Draxler, I. & Tatarsky, I. (1990) The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. British Journal of Haematology, 74, 424-431.
2. Folkman, J. (1995) Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. New England Journal of Medicine, 333, 1757-1763.
3. Neben, K., Moehler, T., Egerer, G., Kraemer, A., Hillengass, J., Benner, A., Ho, A.D. & Goldschmidt, H. (2001) High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clinical Cancer Research, 7, 2675-2681.
4. Neben, K., Mytilineos, J., Moehler, T.M., Preiss, A., Kraemer, A., Ho, A.D., Opelz, G. & Goldschmidt, H. (2002) Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood, 100, 2263-2265.
5. Rajkumar, S.V. & Witzig, T.E. (2000) A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treatment Review, 26, 351-362.
6. Rajkumar, S.V., Leong, T., Roche, P.C., Fonseca, R., Dispenzieri, A., Lacy, M.Q., Lust, J.A., Witzig, T.E., Kyle, R.A., Gertz, M.A. & Greipp, P.R. (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clinical Cancer Research, 6, 3111-3116.
7. Rajkumar, S.V., Mesa, R.A., Fonseca, R., Schroeder, G., Plevak, M.F., Dispenzieri, A., Lacy, M.Q., Lust, J.A., Witzig, T.E., Gertz, M.A., Kyle, R.A., Russell, S.J. & Greipp, P.R. (2002) Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clinical Cancer Research, 8, 2210-2216.
8. Sezer, O., Niemoller, K., Eucker, J., Jakob, C., Kaufmann, O., Zavrski, I., Dietel, M. & Possinger, K. (2000) Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Annals of Hematology, 79, 574-577.
9. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565-1571.
10. Weber, D., Albitar, M., Delasalle, K., Dey, A., Rankin, K., Gavino, M., Walker, P. & Alexanian, R. (2002) Correlation of peripheral blood plasma levels of angiogenesis factors with treatment of thalidomide (T) or thalidomide-dexamethasone (TD) in previously untreated patients with multiple myeloma (MM). Blood, 100, 808a-809a.